Redline of Final Rule Revising the Confidentiality of Alcohol and Drug Abuse Patient Records Regulations

February 28, 2017 Alerts and Newsletters

Verrill Dana's Health Care Group previously published an alert regarding the publication, on January 18, 2017, of a final rule revising the Confidentiality of Alcohol and Drug Abuse Patient Records regulations, commonly known as "Part 2" (the "Final Rule"), for the first time in 29 years. We have created a redlined version comparing the longstanding version of Part 2 against the Final Rule.

The Final Rule was scheduled to take effect on February 17, 2017, but, on January 20, 2017, the incoming Administration issued a freeze on recently published, but not yet effective, regulations, including the Final Rule. The Final Rule will therefore not become effective until March 21, 2017, at the earliest. Under the regulatory freeze, federal agencies are currently reviewing any recently published, but not yet effective, regulations for questions of fact, law, and policy. If no questions exist, the regulations will be effective 60 days after the January 20th freeze was issued, on March 21st. If questions do exist, the agency at issue, SAMHSA in this case, may consider proposing for notice and comment a rule to delay the effective date beyond that 60-day period and may consider potentially proposing further notice-and-comment rulemaking.

Download a PDF of Verrill Dana's redline of the final rule revising the Confidentiality of Alcohol and Drug Abuse Patient Records regulations.

Firm Highlights


European Union GDPR—Institution

Counseled a preeminent health system and academic medical center on its compliance with the European Union General Data Protection Regulation (GDPR) in relation to its clinical and research activities, including its international research studies...


FDA Updates its Guidance on Conducting Clinical Trials During COVID-19 Public Health Emergency

On April 16, 2020, the U.S. Food & Drug Administration (“FDA”) again updated its guidance on the “Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency,” adding seven new questions and...


38 Verrill Attorneys, Across Four Offices, Recognized in 2020 Chambers & Partners Guide

(April 27, 2020) – Verrill has been rated as a Leading Firm in a total of ten categories and subcategories as evaluated by London-based Chambers & Partners , one of the world's most respected...


Michael K. Fee to Lead Verrill’s Nationally-Recognized Health Care and Life Sciences Practice Amidst Recent Changes

(August 31, 2020) – Verrill is pleased to announce Michael K. Fee as the new leader of Verrill’s nationally-recognized Health Care & Life Sciences Group. The Group has a long history of representing a...


Multi-Site Global Research

Developed and negotiated site and coordinating center agreements in connection with a multi-site, international, National Institutes of Health (NIH)-funded study, and advised on regulatory issues related to the conduct of the study and subsequent...


EU-U.S. Privacy Shield Invalidated: Does Your Company Have a Plan B?

On Thursday, July 16, 2020, the Court of Justice of the European Union (“CJEU”) invalidated the EU-U.S. Privacy Shield (“Privacy Shield”) in Data Protection Commissioner v. Facebook Ireland and Maximillian Schrems (Case C-311/18...


Conflicts of Interest

Reviewed medical center's systems, policies and procedures for identifying, assessing, and managing investigator and institutional conflicts of interest.


News Flash: HHS Issues Statement Removing Premarket Review Requirements for Laboratory Developed Tests (“LDTs”), Including COVID-19 LDTs

What happened? On August 19, 2020, the U.S. Department of Health and Human Services (“HHS”) issued a single paragraph statement rescinding U.S. Food and Drug Administration (“FDA”) guidance documents concerning premarket review of Laboratory...


Nearly 80 Verrill Attorneys Recognized by Best Lawyers® 2021, Including a Dozen Named Lawyers of the Year

(August 24, 2020) – Nearly 80 Verrill attorneys were recognized as "Best Lawyers" by Best Lawyers® 2021 , including 12 attorneys named “Lawyer of the Year,” a distinguished recognition for only a single lawyer...


FDA Issues Guidance on IRB Review of Non-Emergency Individual Patient Expanded Access Requests for Investigational Drugs and Biological Products to Treat COVID-19

Prompted by a substantial increase in requests for individual patient access to investigational drugs and biologics to treat COVID-19, the U.S. Food & Drug Administration (“FDA”) issued guidance on June 2, 2020 that outlines...